The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chepurnenko S.A.

Rostov State Medical University, Rostov-on-Don, Russia;
Rostov Regional Clinical Hospital, Rostov-on-Don, Russia

Shavkuta G.V.

Rostov State Medical University, Rostov-on-Don, Russia

Nasytko A.D.

Rostov State Medical University, Rostov-on-Don, Russia

Mitral regurgitation due to papillary-chordal dysfunction, the possibility of drug therapy

Authors:

Chepurnenko S.A., Shavkuta G.V., Nasytko A.D.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2018;11(6): 66‑70

DOI: 10.17116/kardio20181106166

Read: 4973 times

Download PDF (RU)
Contact the author
Table of contents

MITRAL REGURGITATION DUE TO PAPILLARY-CHORDAL DYSFUNCTION, THE POSSIBILITY OF DRUG THERAPY
MITRAL REGURGITATION DUE TO PAPILLARY-CHORDAL DYSFUNCTION, THE POSSIBILITY OF DRUG THERAPY

To cite this article:

Chepurnenko SA, Shavkuta GV, Nasytko AD. Mitral regurgitation due to papillary-chordal dysfunction, the possibility of drug therapy. Russian Journal of Cardiology and Cardiovascular Surgery. 2018;11(6):66‑70. (In Russ.)
https://doi.org/10.17116/kardio20181106166

 
ЭндоКард
Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Mode­rate ischemic mitral insu­fficiency with severe left ventricular dysfunction: surgical treatment depe­nding on predictors of adve­rse long-term outcomes. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):651-659
Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chro­nic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60
Labo­ratory biomarkers for the prognosis of chro­nic heart failure. Labo­ratory Service. 2024;(3):5-16
Diaphragm dysfunction as a prognostic criterion of exte­rnal respiratory impairment and nece­ssary extracorporeal membrane oxygenation in patients with chro­nic heart failure. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):38-45
The pote­ntials of the six-minute walking test in clinical practice auto­matization and adva­nced features. Russian Journal of Preventive Medi­cine. 2024;(12):122-127
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Clinical and phenotypical profiles of patients with chro­nic heart failure with preserved ejection fraction. Russian Journal of Preventive Medi­cine. 2025;(1):83-88
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
Dyna­mics of vector electrocardiography para­meters in patients with chro­nic heart failure under opti­mal drug therapy. Russian Cardiology Bulletin. 2025;(1):57-63
Abstract:

Abstract It is presented clinical case of severe mitral insufficiency in 63-years-old woman with subacute myocarditis. Because of emergence of the new class of angiotensin receptors and neprilizin inhibitors in Russia, ramipril was replaced with valsartan/sacubitryl. Reduced left ventricular volume and severity of mitral regurgitation due to papillary-chordal dysfunction were observed.

Keywords:

mitral regurgitation
papillary-chordal dysfunction
sacubitryl/valsartan
chronic heart failure

Authors:

Chepurnenko S.A.

Rostov State Medical University, Rostov-on-Don, Russia;
Rostov Regional Clinical Hospital, Rostov-on-Don, Russia

Shavkuta G.V.

Rostov State Medical University, Rostov-on-Don, Russia

Nasytko A.D.

Rostov State Medical University, Rostov-on-Don, Russia

Close metadata

References:

  1. Votta E, et al. 3-D computational analysis of the stress distribution on the eaflets after edge-to-edge repair of mitral regurgitation. Edge-to-edge repair-induced stresses. 2014;9312-096.
  2. Lopina NA, et al. Clinical case of acute chord rupture of the mitral valve posterior leaflet in older patient with comorbidities. 2015;1(3):2313-8956. (In Russ.)
  3. Bokeria OL. Sudden cardiac death and defects of the mitral and aortic valves. Annals of arrhythmology. 2013;10(3):162-170. (In Russ.)
  4. Enriques-Sarano M, et al. Quantitative determinants of the outcome of asymptomaticmitral regurgitation. N Engl J Med. 2005;352:875-883.
  5. Rybakova MK, et al. Echocardiography from M.K. Fisherman’s. M.: Publishing house «Vidar». 2016;600. (In Russ.)
  6. Alain Cohen-Solal, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129-2120.
  7. Scott D. Solomon et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction. 2016;9:e002744. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002744
  8. Feldman AM. Valsartan/Sacubitril for heart failure reconciling disparities between preclinical and clinical investigations. 2016;315(1):25-26. https://doi.org/10.1001/jama.2015.17632
  9. Stolov SV, et al. The results of the use of systemic enzyme therapy in the complex treatment of coronary atherosclerosis. The attending physician. 2013;6(13). (In Russ.)
  10. Solomon SD, et al. Influence of ejection fraction on outcomes and efficacy of Sacubitril/Valsartan (LCZ696) in heart failure with reduced ejection fraction. 2016;9:e002744. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002744
  11. Claggett B, et al. Estimating the long-term treatment benefits of Sacubitril–Valsartan. 2015;373:2289-2290. https://doi.org/10.1056/NEJMc1509753
  12. Trueman D, et al. The cost-effectiveness of Sacubitril/Valsartan for the treatment of chronic heart failure with reduced ejection fraction in England and Scotland: applying real-world evidence to enhance generalisability to A UK population. 2016;19(7):A655. https://doi.org/10.1016/j.jval.2016.09.1772
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.